Skip to main content
. 2023 Jun 28;129(3):426–443. doi: 10.1038/s41416-023-02313-y

Fig. 7. FOSL2 promotes Treg cell recruitment through CCL28.

Fig. 7

a–d Scheme representing the experimental procedure (a), representative tumour image (b), tumour weight (c), and tumour growth curves (d) of C57BL/6 mice injected subcutaneously with Vector and oe-FOSL2 PanO2 cells with treatment of CCL28 neutralising antibody or IgG. e Representative flow staining (left panel) and frequency (right panel) of Treg cells in tumour xenograft of indicated groups. f Representative flow staining (left panel) and frequency (right panel) of CD8+ T cells in tumour xenograft of indicated groups. g The frequency of CD4+ T cells in tumour xenograft of indicated groups. h The level of VEGFA protein in the serum of Vector or oe-FOSL2 mice following administration of anti-CCL28 antibody or IgG, as determined by ELISA. i Representative immunofluorescence staining (left panel) and quantitation (right panel) of mean fluorescence intensity of CD31 in indicated groups. Data are representative shown as mean ± SD or SEM (**P < 0.01; ***P < 0.001; ns not significant).